Consequently, an ongoing clinical trial in SCA3 patients is testing the safety and efficacy of an anti-ATXN3 ASO (ClinicalTrials.gov identifier: NCT05160558, accessed on 20 January 2023), while another is testing the safety and efficacy of an anti-ATXN2 ASO in ALS patients (ClinicalTrials.gov identifier: NCT04494256, accessed on 20 January 2023). This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.